Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients with Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease on Presentation to Hospital

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 613 KB, PDF-dokument

  • Rebecca J. Lee
  • Oskar Wysocki
  • Cong Zhou
  • Rohan Shotton
  • Ann Tivey
  • Louise Lever
  • Joshua Woodcock
  • Laurence Albiges
  • Angelos Angelakas
  • Dirk Arnold
  • Theingi Aung
  • Kathryn Banfill
  • Mark Baxter
  • Fabrice Barlesi
  • Arnaud Bayle
  • Benjamin Besse
  • Talvinder Bhogal
  • Hayley Boyce
  • Fiona Britton
  • Antonio Calles
  • Luis Castelo-Branco
  • Ellen Copson
  • Adina E. Croitoru
  • Sourbha S. Dani
  • Elena Dickens
  • Leonie Eastlake
  • Paul Fitzpatrick
  • Stephanie Foulon
  • Henrik Frederiksen
  • Hannah Frost
  • Sarju Ganatra
  • Spyridon Gennatas
  • Fabio Gomes
  • Donna M. Graham
  • Christina Hague
  • Kevin Harrington
  • Michelle Harrison
  • Laura Horsley
  • Richard Hoskins
  • Prerana Huddar
  • Zoe Hudson
  • Lasse H. Jakobsen
  • Nalinie Joharatnam-Hogan
  • Sam Khan
  • Umair T. Khan
  • Khurum Khan
  • Christophe Massard
  • Alec Maynard
  • Hayley McKenzie
  • Olivier Michielin
  • Anne C. Mosenthal
  • Berta Obispo
  • Rushin Patel
  • George Pentheroudakis
  • Solange Peters
  • Kimberly Rieger-Christ
  • Timothy Robinson
  • Jacobo Rogado
  • Emanuela Romano
  • Michael Rowe
  • Marina Sekacheva
  • Roseleen Sheehan
  • Julie Stevenson
  • Alexander Stockdale
  • Anne Thomas
  • Lance Turtle
  • David Viñal
  • Jamie Weaver
  • Sophie Williams
  • Caroline Wilson
  • Carlo Palmieri
  • Donal Landers
  • Timothy Cooksley
  • Caroline Dive
  • André Freitas
  • Anne C. Armstrong

PURPOSEPatients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring for early intervention are critical. We sought to identify features of COVID-19 disease in patients with cancer predicting severe disease and build a decision support online tool, COVID-19 Risk in Oncology Evaluation Tool (CORONET).METHODSPatients with active cancer (stage I-IV) and laboratory-confirmed COVID-19 disease presenting to hospitals worldwide were included. Discharge (within 24 hours), admission (≥ 24 hours inpatient), oxygen (O2) requirement, and death were combined in a 0-3 point severity scale. Association of features with outcomes were investigated using Lasso regression and Random Forest combined with Shapley Additive Explanations. The CORONET model was then examined in the entire cohort to build an online CORONET decision support tool. Admission and severe disease thresholds were established through pragmatically defined cost functions. Finally, the CORONET model was validated on an external cohort.RESULTSThe model development data set comprised 920 patients, with median age 70 (range 5-99) years, 56% males, 44% females, and 81% solid versus 19% hematologic cancers. In derivation, Random Forest demonstrated superior performance over Lasso with lower mean squared error (0.801 v 0.807) and was selected for development. During validation (n = 282 patients), the performance of CORONET varied depending on the country cohort. CORONET cutoffs for admission and mortality of 1.0 and 2.3 were established. The CORONET decision support tool recommended admission for 95% of patients eventually requiring oxygen and 97% of those who died (94% and 98% in validation, respectively). The specificity for mortality prediction was 92% and 83% in derivation and validation, respectively. Shapley Additive Explanations revealed that National Early Warning Score 2, C-reactive protein, and albumin were the most important features contributing to COVID-19 severity prediction in patients with cancer at time of hospital presentation.CONCLUSIONCORONET, a decision support tool validated in health care systems worldwide, can aid admission decisions and predict COVID-19 severity in patients with cancer.

TidsskriftJCO clinical cancer informatics
Antal sider18
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
R.J.L., T.R., and J.W. were supported by the National Institute for Health Research as Clinical Lecturers. T.B. was supported by the National Institute for Health Research as an academic clinical fellow. U.T.K. is an MRC Clinical Training Fellow based at the University of Liverpool supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which was funded by the Medical Research Council (Award Ref. MR/N025989/1), The Liverpool Experimental Cancer Medicine Centre for providing infrastructure support (Grant Reference: C18616/A25153), and The Clatterbridge Cancer charity (North West Cancer Research). C.D. was funded by CRUK Core funding to Manchester Institute (C5757/A27412) and was supported by the CRUK Manchester Centre Award (C5759/A25254) and by the NIHR Manchester Biomedical Research Centre. C.Z. was funded by the CRUK Manchester Center Award (C5759/A25254), J.S. and P.F. were funded by the CRUK Accelerator Award (29374). This research was funded in part by the Wellcome Trust (205228/Z/16/Z). L.T. was also supported by the National Institute for Health Research Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections (NIHR200907) at the University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. L.T. is based at University of Liverpool. M.S. was supported by the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Centers Digital biodesign and personalized healthcare. No. 075-15-2020-926. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, and the Department of Health or Public Health England. Funding for COVID-19 work was provided by The Christie Charitable fund (1049751).

Publisher Copyright:
© American Society of Clinical Oncology.

Antal downloads er baseret på statistik fra Google Scholar og

Ingen data tilgængelig

ID: 328231106